# A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-phase-ii-study-of-biweekly-paclitaxel-and-cisplatin-chemotherapy-for-recurrent/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jing Huang,Yi Zhou,Hong‐Tu Zhang,Tao Qu,Yousheng Mao,Hongxia Zhu,Lanping Quan,Puyuan Xing,Jinwan Wang,Jie He,Ningzhi Xu,Yan Sun |
| Citations | 79 |
| DOI | 10.1007/s12032-012-0343-4 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2042844347 |
| PMID | 23263828 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Puyuan Xing](https://scholariq.org/researchers/puyuan-xing/)

## Paper primary topic

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Paper topics

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.